Dr Reddy’s has entered an exclusive licensing agreement with Immutep to develop and commercialise its immunotherapy Eftilagimod Alfa across key global markets, with Immutep eligible for milestone payments and royalties.
Dr Reddy’s has entered an exclusive licensing agreement with Immutep to develop and commercialise its immunotherapy Eftilagimod Alfa across key global markets, with Immutep eligible for milestone payments and royalties.